# TICAM1

## Overview
TICAM1, or TIR domain-containing adaptor molecule 1, is a gene that encodes the adaptor protein TRIF, which is integral to the immune system's response to pathogens. TRIF is a key component in the Toll-like receptor (TLR) signaling pathways, particularly in the pathways associated with TLR3 and TLR4. This protein plays a crucial role in mediating the immune response by facilitating the production of type I interferons and other inflammatory cytokines. Structurally, TRIF is characterized by several domains that contribute to its function, including a TIR domain essential for protein-protein interactions within the signaling pathways. The protein's ability to interact with various signaling molecules and adaptors underscores its central role in modulating immune responses and its involvement in a wide range of immune-related disorders (Ullah2016TRIF-dependent; Miyashita2021TICAM-1/TRIF).

## Structure
The molecular structure of TICAM1 (TIR domain-containing adaptor molecule 1), also known as TRIF, is characterized by several distinct domains that play crucial roles in its function within Toll-like receptor (TLR) signaling pathways. The N-terminal domain (NTD) of TICAM1, consisting of the first 176 amino acids, forms a protease-resistant structure composed of eight alpha-helices, which is significant for the activation of IRF-3 as it recruits the IRF-3-activating kinases TBK1 and IKK (Tatematsu2010A). This domain also contains a binding site for tumor necrosis factor receptor-associated factor (TRAF) proteins and is involved in autoinhibitory interactions with the TIR domain of TICAM1 (Kumeta2014The).

The TIR domain, essential for homo-oligomerization and heterotypic interactions with TLR3 and TICAM-2 TIR domains, includes a series of secondary structural elements such as five parallel Î²-strands and six Î±-helices (Enokizono2013Structures). Mutations in this domain, such as Pro434 substituted to His, can disrupt homo-oligomerization and affect NF-ÎºB and IRF-3 activation while retaining the ability for heterotypic TIR-TIR interactions (Kumeta2014The).

The C-terminal region of TICAM1 includes a receptor interacting protein 1 (RIP1) binding motif (RHIM), crucial for NF-ÎºB activation and inducing apoptosis by interacting with RIP1 at the RHIM domain (Tatematsu2010A). Upon stimulation, TICAM1 undergoes oligomerization through its TIR domain and the C-terminal region, forming a complex known as the TICAM1 signalosome (Tatematsu2010A). This structural arrangement suggests a resting form of TICAM1 where the NTD folds into the TIR domain structure, preventing homodimerization and access of downstream signaling molecules to TICAM1 (Tatematsu2010A).

## Function
TICAM1, also known as TRIF, is a critical adaptor protein in Toll-like receptor (TLR) signaling pathways, specifically involved in the pathways triggered by TLR3 and TLR4. It plays a pivotal role in the immune response to pathogens by mediating the production of type I interferons and other inflammatory cytokines. TICAM1 utilizes its TIR domain to interact with TLR3, facilitating the organization of signaling complexes that are essential for the activation of transcription factors such as NF-ÎºB and IRF3. These transcription factors drive the expression of genes involved in immune and inflammatory responses (Ullah2016TRIF-dependent).

In the context of TLR3 signaling, TICAM1 binds specifically to the TIR domain of TLR3, which is crucial for the subsequent activation of downstream signaling pathways leading to the production of interferon-beta (IFN-Î²), a key antiviral cytokine. This interaction is necessary for the full activation of IFN-Î² production following TLR3 stimulation by dsRNA (Oshiumi2003TICAM-1).

Moreover, TICAM1 is involved in TLR4 signaling, where it associates with TICAM2 (TRAM) as an adaptor, necessary for the function of the cytoplasmic viral dsDNA sensor cGAS, which requires STING to induce type I IFN expression. This highlights its broader role in immune regulation beyond just antiviral responses (Miyashita2021TICAM-1/TRIF).

## Clinical Significance
Mutations and polymorphisms in the TICAM1 gene have been associated with various diseases and conditions, highlighting its clinical significance. In children, specific single nucleotide polymorphisms (SNPs) in TICAM1, such as rs35747610, are linked to community-acquired pneumonia (CAP), influencing susceptibility, severity, and the risk of developing sepsis (Yang2020Correlation). Additionally, variations in TICAM1 have been implicated in the immune response to Rift Valley Fever, with certain mutations correlating with viral meningitis and related symptoms (Yang2020Correlation).

Beyond infectious diseases, TICAM1 polymorphisms are also associated with autoimmune and inflammatory conditions. For instance, alterations in TICAM1 expression or function can exacerbate inflammatory conditions such as experimental autoimmune encephalomyelitis, a model for multiple sclerosis, by affecting cytokine and chemokine expression (Miyashita2021TICAM-1/TRIF).

Furthermore, TICAM1 has been linked to cancer, particularly papillary thyroid cancer (PTC). Studies have identified SNPs in TICAM1 that significantly associate with the risk of developing PTC, suggesting a potential role in thyroid carcinogenesis (Sigurdson2016Selected). These findings underscore the importance of TICAM1 in various pathological conditions, ranging from infectious diseases to cancer, mediated through its role in immune system regulation.

## Interactions
TICAM1, also known as TRIF, is a central adaptor protein in the Toll-like receptor (TLR) signaling pathways, particularly TLR3 and TLR4, playing a pivotal role in the immune response. It interacts with various proteins to mediate the activation of transcription factors such as NF-ÎºB and IRF3, which are crucial for the production of type I interferons and other inflammatory cytokines. TICAM1 forms a complex with TLR3, and this interaction is specific as it does not bind with other TLRs like TLR2 and TLR4, nor with the TLR3 dysfunctional mutant A795H (Oshiumi2003TICAM-1). Additionally, TICAM1 interacts with TRAF family proteins, including TRAF1, TRAF2, and TRAF6, with the C-terminal domains of TRAF2 and TRAF6 binding to the N-terminal region of TICAM1 (Sasai2010Direct). The protein also associates with TICAM2, another adaptor molecule, through specific amino acids facilitating electrostatic interactions, which are essential for TLR4-mediated signaling pathways (Funami2017Functional). Furthermore, TICAM1 interacts with various signaling molecules such as RIP1, RIP3, NAP1, and TBK1, forming part of the TICAM1 signalosome complex that activates transcription factors like NF-ÎºB, AP-1, and IRF-3 (Funami2017Functional).


## References


[1. (Miyashita2021TICAM-1/TRIF) Yusuke Miyashita, Takahisa Kouwaki, Hirotake Tsukamoto, Masaaki Okamoto, Kimitoshi Nakamura, and Hiroyuki Oshiumi. Ticam-1/trif associates with act1 and suppresses il-17 receptorâmediated inflammatory responses. Life Science Alliance, 5(2):e202101181, November 2021. URL: http://dx.doi.org/10.26508/lsa.202101181, doi:10.26508/lsa.202101181. (8 citations) 10.26508/lsa.202101181](https://doi.org/10.26508/lsa.202101181)

[2. (Kumeta2014The) Hiroyuki Kumeta, Hiromi Sakakibara, Yoshiaki Enokizono, Kenji Ogura, Masataka Horiuchi, Misako Matsumoto, Tsukasa Seya, and Fuyuhiko Inagaki. The n-terminal domain of tir domain-containing adaptor molecule-1, ticam-1. Journal of Biomolecular NMR, 58(3):227â230, February 2014. URL: http://dx.doi.org/10.1007/s10858-014-9819-1, doi:10.1007/s10858-014-9819-1. (10 citations) 10.1007/s10858-014-9819-1](https://doi.org/10.1007/s10858-014-9819-1)

[3. (Enokizono2013Structures) Yoshiaki Enokizono, Hiroyuki Kumeta, Kenji Funami, Masataka Horiuchi, Joy Sarmiento, Kazuo Yamashita, Daron M. Standley, Misako Matsumoto, Tsukasa Seya, and Fuyuhiko Inagaki. Structures and interface mapping of the tir domain-containing adaptor molecules involved in interferon signaling. Proceedings of the National Academy of Sciences, 110(49):19908â19913, November 2013. URL: http://dx.doi.org/10.1073/pnas.1222811110, doi:10.1073/pnas.1222811110. (70 citations) 10.1073/pnas.1222811110](https://doi.org/10.1073/pnas.1222811110)

[4. (Oshiumi2003TICAM-1) Hiroyuki Oshiumi, Misako Matsumoto, Kenji Funami, Takashi Akazawa, and Tsukasa Seya. Ticam-1, an adaptor molecule that participates in toll-like receptor 3âmediated interferon-Î² induction. Nature Immunology, 4(2):161â167, January 2003. URL: http://dx.doi.org/10.1038/ni886, doi:10.1038/ni886. (1607 citations) 10.1038/ni886](https://doi.org/10.1038/ni886)

[5. (Yang2020Correlation) Yong Yang, Suiyu Yang, Zongbo Chen, and Li Liu. Correlation between ticam1 gene polymorphisms and communityâacquired pneumonia in children. Journal of Biochemical and Molecular Toxicology, April 2020. URL: http://dx.doi.org/10.1002/jbt.22503, doi:10.1002/jbt.22503. (2 citations) 10.1002/jbt.22503](https://doi.org/10.1002/jbt.22503)

[6. (Sasai2010Direct) Miwa Sasai, Megumi Tatematsu, Hiroyuki Oshiumi, Kenji Funami, Misako Matsumoto, Shigetsugu Hatakeyama, and Tsukasa Seya. Direct binding of traf2 and traf6 to ticam-1/trif adaptor participates in activation of the toll-like receptor 3/4 pathway. Molecular Immunology, 47(6):1283â1291, March 2010. URL: http://dx.doi.org/10.1016/j.molimm.2009.12.002, doi:10.1016/j.molimm.2009.12.002. (116 citations) 10.1016/j.molimm.2009.12.002](https://doi.org/10.1016/j.molimm.2009.12.002)

[7. (Sigurdson2016Selected) Alice J. Sigurdson, Alina V. Brenner, James A. Roach, Lilia Goudeva, JÃ¶rg A. MÃ¼ller, Kai Nerlich, Christoph Reiners, Robert Schwab, Liliane Pfeiffer, Melanie Waldenberger, Melissa Braganza, Li Xu, Erich M. Sturgis, Meredith Yeager, Stephen J. Chanock, Ruth M. Pfeiffer, Michael Abend, and Matthias Port. Selected single-nucleotide polymorphisms infoxe1,serpina5,fto,evpl,ticam1andscarb1are associated with papillary and follicular thyroid cancer risk: replication study in a german population. Carcinogenesis, 37(7):677â684, April 2016. URL: http://dx.doi.org/10.1093/carcin/bgw047, doi:10.1093/carcin/bgw047. (47 citations) 10.1093/carcin/bgw047](https://doi.org/10.1093/carcin/bgw047)

[8. (Funami2017Functional) Kenji Funami, Misako Matsumoto, Hiroyuki Oshiumi, Fuyuhiko Inagaki, and Tsukasa Seya. Functional interfaces between ticam-2/tram and ticam-1/trif in tlr4 signaling. Biochemical Society Transactions, 45(4):929â935, June 2017. URL: http://dx.doi.org/10.1042/bst20160259, doi:10.1042/bst20160259. (42 citations) 10.1042/bst20160259](https://doi.org/10.1042/bst20160259)

[9. (Ullah2016TRIF-dependent) M Obayed Ullah, Matthew J Sweet, Ashley Mansell, Stuart Kellie, and Bostjan Kobe. Trif-dependent tlr signaling, its functions in host defense and inflammation, and its potential as a therapeutic target. Journal of Leukocyte Biology, 100(1):27â45, May 2016. URL: http://dx.doi.org/10.1189/jlb.2ri1115-531r, doi:10.1189/jlb.2ri1115-531r. (139 citations) 10.1189/jlb.2ri1115-531r](https://doi.org/10.1189/jlb.2ri1115-531r)

[10. (Tatematsu2010A) Megumi Tatematsu, Akihiro Ishii, Hiroyuki Oshiumi, Masataka Horiuchi, Fuyuhiko Inagaki, Tsukasa Seya, and Misako Matsumoto. A molecular mechanism for toll-il-1 receptor domain-containing adaptor molecule-1-mediated irf-3 activation. Journal of Biological Chemistry, 285(26):20128â20136, June 2010. URL: http://dx.doi.org/10.1074/jbc.m109.099101, doi:10.1074/jbc.m109.099101. (55 citations) 10.1074/jbc.m109.099101](https://doi.org/10.1074/jbc.m109.099101)